RESEARCH PAPER
Metallothionein and manganese concentrations in breast cancer and mastopathic tissues
 
More details
Hide details
1
Independent Laboratory for Cell Metabolism, Institute of Rural Health, Lublin, Poland
2
Oncological Centre, Lublin, Poland
3
Department of Bromatology, Medical University, Lublin, Poland
CORRESPONDING AUTHOR
Bolesław Floriańczyk   

Independent Laboratory for Cell Metabolism, Institute of Rural Health, Jaczewskiego 2, 20-950 Lublin, Poland.
 
J Pre Clin Clin Res. 2011;5(2):63–65
KEYWORDS
ABSTRACT
Metallothionein (MT) takes part in the homeostasis of the metals which are necessary for proper metabolism, and they also take part in the detoxication of toxic metals from the tissues. Additionally, they protect the tissues from the eff ects of reactive, oxygen species, radiation, mutagens, and from electrophilic pharmacologic agents used in cancer therapy. Manganese (Mn) – an essential microelement - seems to be very important during development. Mn takes a part as cofactor of the enzymes regulating metabolism. This microelement also participates in reduction-oxidation reactions. An example of such a reaction is the superoxide dismutase (MnSOD) activity, with manganese as the enzyme component. It is thought that manganese and manganese superoxide dismutase play an important role in the diff erentiating cells. The aim of this work was to evaluate whether the neoplastic process changes the values of metallothionein and manganese. The examined material consisted of samples of breast tumour taken during surgery. The level of the metallothionein was determined by the cadmium- hemoglobin affi nity assay, using the cadmium isotope (109Cd); the concentration of manganese was determined by atomic absorption spectrometry. It was found that metallothionein and manganese concentration in breast cancer was higher in comparison with mastopathic lesions of the breast. Neoplastic cells contained more metallothioneins (by 330%) and more manganese (by 25%). Negative correlations were found between the amount of metallothionein and the level of manganese in mastopathic lesions (r = -0.57, p < 0.05), and in breast cancer (r = -0.32, p > 0.05). The relatively high level of metallothionein and manganese in the neoplastic tissues indicates the important role may play in the metabolism of cancer cells. Negative correlation between the concentration of metallothionein and manganese ions found in mastopathic tissues and breast cancer indicates that their roles are opposite.
 
REFERENCES (29)
1.
Floriańczyk B. Factors inducing synthesis of metallothioneins. Post Hig Med Dośw 2000;5:687-697.
 
2.
Sens MA, Somji S, Lamm DL, Garrett SH, Slovinsky F, Todd JH, Sens DA. Metallothionein isoform 3 as a potential biomarker for human bladder cancer. Environ Health Perspect 2000;108:413-418.
 
3.
Smith DJ, Jaggi M, Zhang W, Galich A, Du C, Sterrett SP, Smith LM, Balaji KC. Metallothioneins and resistance to cisplatin and radiation in prostate cancer. Urology 2006;67:1341-1347.
 
4.
Th irumoorthy N, Manisenthil Kumar KT, Shyam Sundar A, Panayappan L, Chatterjee M. Metallothionein: An overview. World J Gastroenterol 2007;13(7):993-996.
 
5.
St.Clair DK, Oberley TD, Muse KE, St.Clair WH. Statement of manganese superoxide dismutase promotes cellular diff erentiation. Free Rad Biol Med 1994;16:275-282.
 
6.
Mitrunen K, Sillanpaa P, Eskelinen M, Kosma V-M, Benhamou S, Uusitupa M, Hirvonen A. Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk Carcinogenesis 2001;22:827-829.
 
7.
Wysocki PJ. Epotilony – nowa klasa inhibitorow wrzeciona kariokinetycznego w leczeniu raka piersi. (Epothilones – a new class of microtubule-targing agents in the treatment of breast cancer). Wspoł Onkol 2008;12:343-348.
 
8.
Bay B-H, Jin R, Huang J, Tan PH. Metallothionein as a prognostic biomarker in breast cancer. Exper Biol Med 2006;231:1516-1521.
 
9.
Suzuki S, Masui Y, Ohnuki M, Miyakoda G, Mori T, Nakajima K, Sato M. Induction of metallothionein synthesis by cilostazol in mice and in human cultured neuronal cell lines. Biol Pharm Bull 2007;30:791-794.
 
10.
Robert VP, Hutter MD. Th e role of the pathologist in breast cancer management. Supplement to Cancer Journal of the American Cancer Society 1990;15:1363-1372.
 
11.
Eaton DL, Cherian MG: Determination of metallothionein in tissues by cadmium-hemoglobin affi nity assay. Methods in Enzymology 1991; 205.
 
12.
Saari E, Paaso A. Mineral element composition of Finish foods. Acta Agric Scand Suppl 1980;22:15-18.
 
13.
Sato M, Kondoh M. Recent studies on metallothionein: protection against toxicity of heavy metals and oxygen free radicals. Tohoku J Exp Med 2002;196:9-22.
 
14.
Bremner J, Beattie JH. Metallothionein and the trace metals. Ann Rev Nutr 1990;10:63-83.
 
15.
Floriańczyk B. Function of metallothionein in the body. Postępy Hig Med Dośw 1996;50:375-382.
 
16.
Jin R, Huang J, Tan P-H, Bay B-H. Clinicopathologigical signifi cance of metallothioneins in breast cancer. Path Oncol Res 2004;10:74-79.
 
17.
Zhang R, Zhang H, Wei H, Luo X. Expression of metallothionein in invasive ductal breast cancer in relation to prognosis. J Environ Pathol Toxicol Oncol 2000;19:95-97.
 
18.
Floriańczyk B, Osuchowski J, Kaczmarczyk R, Trojanowski T. Infl uence of metallothioneins on zinc and copper distribution in brain tumours. Folia Neuropathol 2003;41:11-14.
 
19.
Floriańczyk B, Grzybowska L. Metallothionein levels in cell fractions from breast cancer tissues. Acta Oncol 2000;39:141-143.
 
20.
Galeotti T, Palombini G, van Rossum GDU. Manganese content and high affi nity transport in liver and hepatoma. Arch Biochem Biophys 1995;322:453-459.
 
21.
Jasani B, Schmid W. Signifi cance of metallothionein overexpression in human tumors. Histopathology 1997;31:211-214.
 
22.
Takeda A, Tamano H, Oku N. Alteration of zinc concentrations in the brain implanted with C6 glioma. Brain Res 2003;965:170-173.
 
23.
Th eocharis SE, Margeli AP, Klijanienko JT, Kouraklis GP. Metallothionein expression in human neoplasia. Histopathology 2004;45:103-118.
 
24.
Floriańczyk B, Karska M. Manganese and metabolism. Adv Clin Exp Med 1998;7:207-211.
 
25.
Culotta VC, Yang M, O’Halloran TV. Activation of superoxide dismutase: putting the metal to the pedal. Biochim Biophys Acta 2006;1763:747-758.
 
26.
Ichikawa J, Kiyama S, Yoshioka T. Renal antioxidant - their regulation and function. Kidney Inter 1994;45:1-9.
 
27.
Palmiter RD. Regulation of metallothionein genes by heavy metals appears to be mediated by a zinc-sensitive inhibitor that interacts with a constitutively active transcription factor MTF-1. Proc Natl Acad Sci USA 1994;91:1219-1223.
 
28.
Floriańczyk B, Stryjecka-Zimmer M. Induction of metallothioneins by ethanol and morphine. Ann Univ Mariae Curie Sklodowska 2001;56:243-247.
 
29.
Cherian MG, Jayasurya A, Bay BH. Metallothionein in human tumors and potential roles in carcinogenesis. Mutat Res 2003;10:201-209.
 
eISSN:1898-7516
ISSN:1898-2395